Milind Desai, ACC 2022: VALOR-HCM trial
Access all of the content
The VALOR-HCM trial showed the benefits of mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. It was a pleasure to speak with Prof. Milind Desai (Cleveland Clinic, Cleveland, OH) about the VALOR-HCM trial including the efficacy and safety endpoints of it and what future studies of mavacamten are planned.
- Could you tell us a little about the VALOR-HCM trial? (00:21)
- What questions remain unanswered about the health benefits of mavacamten, and what future studies are planned? (04:45)
Disclosures: Milind Desai is a consultant for Bristol Myers Squibb and Medtronic.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
Share this Video
Related Videos In Cardiovascular Disease
Divaka Perera, ACC 2023: Myocardial viability in patients with ischaemic left ventricular dysfunction, the REVIVED-BCIS2 trial
The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the REVIVED-BCIS2 trial, its findings and the impact these results will likely […]
Divaka Perera, ACC 2023: Myocardial viability tests for guiding the ischaemic left ventricular dysfunction treatment paradigm
Ischaemic left ventricular dysfunction is encountered frequently by physicians. Myocardial viability tests are utilised as a prospective tool that enables prediction of a patient’s recoverability. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the treatment paradigm for ischaemic left ventricular dysfunction and […]
Zsolt Piroth, TCT 2022: The value of post-PCI FFR and intravascular imaging for cardiovascular failure, a FAME 3 substudy
This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!